About US
Contact us
>>Back
Visterra to present efficacy data on VIS410 against H5N1 influenza
- Publisher：
- Publication：2012/11/2
Visterra has announced that it will be presenting prophylactic and therapeutic efficacy data for VIS410 in the treatment of the H5N1 (Avian Flu) strain of influenza at a conference in Vietnam.
The company's chief medical officer Donna Ambrosino MD will present the data to the International Society for Influenza and Other Respiratory Viruses at its Antiviral Group (AVG) Conference in Hanoi from October 29th to 31st.
The AVG is an independent society of scientific professionals from around the world tasked with arranging international conferences and events devoted to the prevention and treatment of influenza, including seasonal flu and pandemics.
Visterra has analysed proteins to identify a unique site on the influenza hemagglutinin - the substance that encourages cells to agglutinate - that is resistant to mutation. Based on this data, it designed human antibodies that bind to the site and neutralize several groups of influenza A strains.
"We are very pleased to have this opportunity to present and discuss VIS410 at this conference of world leaders focused on improving the global clinical management of influenza," said Dr Ambrosino.
"VIS410's potent efficacy against a broad spectrum of influenza strains, including H5N1, further demonstrates the potential of VIS410 as both a novel therapeutic and a passive immunoprophylactic agent to combat seasonal and pandemic influenza."